[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0607374B8 - gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis - Google Patents

gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis

Info

Publication number
BRPI0607374B8
BRPI0607374B8 BRPI0607374A BRPI0607374A BRPI0607374B8 BR PI0607374 B8 BRPI0607374 B8 BR PI0607374B8 BR PI0607374 A BRPI0607374 A BR PI0607374A BR PI0607374 A BRPI0607374 A BR PI0607374A BR PI0607374 B8 BRPI0607374 B8 BR PI0607374B8
Authority
BR
Brazil
Prior art keywords
neisseria meningitidis
broad
diseases caused
protection against
gna1870
Prior art date
Application number
BRPI0607374A
Other languages
Portuguese (pt)
Inventor
M Granoff Dan
Hou Victor
Original Assignee
Childrens Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital & Res Center At Oakland filed Critical Childrens Hospital & Res Center At Oakland
Publication of BRPI0607374A2 publication Critical patent/BRPI0607374A2/en
Publication of BRPI0607374B1 publication Critical patent/BRPI0607374B1/en
Publication of BRPI0607374B8 publication Critical patent/BRPI0607374B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

vacinas de vesículas baseadas em gna187o para proteção de amplo espectro contra doenças causadas por neisseria meningitidis. a presente invenção refere-se geralmente métodos e composições para elicitar uma resposta imunológica contra bactérias da espécie neisseria em um paciente, particularmente contra uma cepa do sorogrupo b de neisseria meningitídís.gna187o-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis. The present invention generally relates to methods and compositions for eliciting an immune response against bacteria of the neisseria species in a patient, particularly against a serogroup b strain of neisseria meningitidis.

BRPI0607374A 2005-01-27 2006-01-23 gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis BRPI0607374B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64791105P 2005-01-27 2005-01-27
PCT/US2006/002523 WO2006081259A2 (en) 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Publications (3)

Publication Number Publication Date
BRPI0607374A2 BRPI0607374A2 (en) 2009-09-01
BRPI0607374B1 BRPI0607374B1 (en) 2020-04-22
BRPI0607374B8 true BRPI0607374B8 (en) 2021-05-25

Family

ID=36741009

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607374A BRPI0607374B8 (en) 2005-01-27 2006-01-23 gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis

Country Status (20)

Country Link
US (7) US9034345B2 (en)
EP (3) EP2682126B1 (en)
JP (1) JP4993750B2 (en)
CN (1) CN101107007B (en)
AU (1) AU2006208208B2 (en)
BR (1) BRPI0607374B8 (en)
CA (1) CA2590974C (en)
CY (1) CY1118732T1 (en)
DK (1) DK2682126T3 (en)
ES (1) ES2616294T3 (en)
HK (1) HK1107526A1 (en)
HU (1) HUE033196T2 (en)
LT (1) LT2682126T (en)
MX (1) MX2007008785A (en)
NZ (1) NZ555937A (en)
PL (1) PL2682126T3 (en)
PT (1) PT2682126T (en)
RU (1) RU2432962C2 (en)
SI (1) SI2682126T1 (en)
WO (1) WO2006081259A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210305C (en) 1998-05-01 2005-07-13 希龙公司 Neisseria meningitidis antigens and compositions
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
BR0015137A (en) 1999-10-29 2003-03-25 Chiron Spa Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1897555E (en) 2000-01-17 2014-10-10 Novartis Vaccines & Diagnostic Supplemented omv vaccine against meningococcus
EP2270031A3 (en) 2000-02-28 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of neisserial proteins
JP5511117B2 (en) * 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0607374B8 (en) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (en) * 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
MX2010004271A (en) 2007-10-19 2010-05-03 Novartis Ag Meningococcal vaccine formulations.
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
HUE027249T2 (en) 2008-03-03 2016-10-28 Novartis Ag Compounds and compositions as tlr activity modulators
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
NZ589812A (en) * 2008-05-30 2012-08-31 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
AU2015275311B2 (en) * 2008-10-25 2017-07-13 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
LT2411048T (en) 2009-03-24 2020-06-25 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010127172A2 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
JP2013502918A (en) 2009-08-27 2013-01-31 ノバルティス アーゲー Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
CN102480932B (en) * 2009-09-01 2015-01-14 阿昂梅迪克斯公司 Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using same
MX2012002723A (en) 2009-09-02 2012-04-11 Novartis Ag Immunogenic compositions including tlr activity modulators.
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CA2779839A1 (en) * 2009-11-06 2011-05-12 Children's Hospital & Research Center At Oakland T-cell stimulating protein b and methods of use
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
CN102869377A (en) * 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 Immunogenic composition
CN102802662A (en) 2010-03-18 2012-11-28 诺华有限公司 Adjuvanted vaccines for serogroup B meningococcus
CN102905703B (en) 2010-03-23 2016-09-28 诺华股份有限公司 As TLR2 agonist for treating compound (lipopeptid based on cysteine) and the compositions of infection, inflammation, respiratory disorder etc.
TR201802933T4 (en) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland The modified factor h binding proteins (fhbp) and their method of use.
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
EP2589377B1 (en) * 2010-07-01 2018-10-17 Aeon Medix Inc. Microvesicles derived from cell protoplast, and use thereof
SI3831406T1 (en) 2010-08-23 2024-08-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
EP2729167B1 (en) * 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
RU2014135522A (en) 2012-02-02 2016-03-27 Новартис Аг Promoters for Enhanced Protein Expression at Meningococcus
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
JP5925342B2 (en) 2012-03-09 2016-05-25 ファイザー・インク Neisseria meningitidis composition and method thereof
CN104602704B (en) 2012-06-14 2019-08-06 诺华股份有限公司 Vaccines against serogroup X meningococcus
US10000545B2 (en) 2012-07-27 2018-06-19 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CN104602705A (en) 2012-09-06 2015-05-06 诺华股份有限公司 Combination vaccines with serogroup b meningococcus and D/T/P
CN104602702B (en) * 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 Outer membrane vesicles
JP2016507543A (en) 2013-02-07 2016-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Pharmaceutical composition comprising vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CN105431167A (en) 2013-08-02 2016-03-23 奥克兰儿童医院及研究中心 Non-naturally occurring factor h binding proteins (FHBP) and methods of use thereof
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20230035455A (en) 2014-02-28 2023-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Modified meningococcal fhbp polypeptides
AU2015292615B2 (en) 2014-07-23 2019-10-24 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
CN107249626A (en) 2015-02-19 2017-10-13 辉瑞大药厂 Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3577130A2 (en) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01125328A (en) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados Meningococcus vaccine
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
ES2070312T5 (en) 1988-12-19 2003-05-16 American Cyanamid Co CLASS 1 MENINGOCOCIC EXTERNAL MEMBRANE PROTEIN VACCINE.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
KR100278157B1 (en) 1992-06-25 2001-01-15 장 스테판느 Vaccine Compositions Containing Supplements
NL9201716A (en) * 1992-10-02 1994-05-02 Nederlanden Staat Outer membrane vesicle comprising a group of polypeptides which have at least the immune function of membrane bound outer membrane proteins (OMPs), method of preparation thereof and a vaccine comprising such an outer membrane vesicle.
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
DE69428136T3 (en) 1993-03-23 2008-07-10 Smithkline Beecham Biologicals S.A. 3-0-deacylated monophosphoryl lipid A-containing vaccine compositions
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (en) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション Immunomodulatory oligonucleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2751000B1 (en) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
ES2333069T3 (en) 1997-03-10 2010-02-16 Ottawa Hospital Research Institute USE OF NUCLEIC ACIDS CONTAINING NON-METHYLED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS AN ASSISTANT.
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU753172B2 (en) 1997-06-06 2002-10-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
BR9906927A (en) 1998-01-14 2001-11-20 Chiron Spa Neisseria meningitidis proteins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
CN1210305C (en) 1998-05-01 2005-07-13 希龙公司 Neisseria meningitidis antigens and compositions
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
ES2294821T5 (en) * 1998-11-03 2014-03-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
AU750788B2 (en) 1999-03-19 2002-07-25 Smithkline Beecham Biologicals (Sa) Vaccine
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CN1359426A (en) 1999-04-30 2002-07-17 希龙公司 Neisseria genomic sequences and methods of their use
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (en) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. At least one non-ionic surfactant adjuvant with polyoxyethylene alkyl ether or ester.
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1897555E (en) * 2000-01-17 2014-10-10 Novartis Vaccines & Diagnostic Supplemented omv vaccine against meningococcus
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
JP5511117B2 (en) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
PT2248822T (en) 2001-07-27 2017-02-14 Glaxosmithkline Biologicals Sa Meningococcus adhesins
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
JP4740738B2 (en) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
JP4697706B2 (en) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Polypeptide-vaccine for broad protection against highly virulent meningococcal strains
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
BRPI0607374B8 (en) * 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2326726A4 (en) * 2008-08-27 2011-09-28 Childrens Hosp & Res Ct Oak Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis

Also Published As

Publication number Publication date
HK1107526A1 (en) 2008-04-11
BRPI0607374A2 (en) 2009-09-01
EP1855715A4 (en) 2009-06-17
US10478484B2 (en) 2019-11-19
US9034345B2 (en) 2015-05-19
EP2682126B1 (en) 2016-11-23
US8968748B2 (en) 2015-03-03
CN101107007B (en) 2011-08-17
EP2433647A2 (en) 2012-03-28
AU2006208208A1 (en) 2006-08-03
DK2682126T3 (en) 2017-02-27
SI2682126T1 (en) 2017-03-31
CN101107007A (en) 2008-01-16
CY1118732T1 (en) 2017-07-12
JP2008528597A (en) 2008-07-31
US20080248065A1 (en) 2008-10-09
LT2682126T (en) 2017-02-27
WO2006081259A2 (en) 2006-08-03
US20180369356A1 (en) 2018-12-27
EP1855715B1 (en) 2013-03-13
NZ555937A (en) 2009-05-31
EP2682126A1 (en) 2014-01-08
ES2616294T3 (en) 2017-06-12
MX2007008785A (en) 2008-02-15
US9452208B2 (en) 2016-09-27
RU2007128332A (en) 2009-01-27
US10046043B2 (en) 2018-08-14
RU2432962C2 (en) 2011-11-10
AU2006208208B2 (en) 2011-05-19
JP4993750B2 (en) 2012-08-08
US20120093867A1 (en) 2012-04-19
US20150290312A1 (en) 2015-10-15
US20200138931A1 (en) 2020-05-07
US10857221B2 (en) 2020-12-08
PL2682126T3 (en) 2017-07-31
US20170065699A1 (en) 2017-03-09
WO2006081259A3 (en) 2007-03-01
EP1855715A2 (en) 2007-11-21
CA2590974C (en) 2017-10-03
US11801293B2 (en) 2023-10-31
CA2590974A1 (en) 2006-08-03
US20210308247A1 (en) 2021-10-07
EP2433647A3 (en) 2012-06-06
PT2682126T (en) 2017-02-28
BRPI0607374B1 (en) 2020-04-22
HUE033196T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
BRPI0607374B8 (en) gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis
BR112013005329A2 (en) non-lipid variants of neisseria meningitidis orf2086 antigens
ECSP034447A (en) VACCINES FOR PROTECTION OF SPECTRO SPECTRUM AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
IN2014DN08830A (en)
SG178954A1 (en) Immunogenic compositions including tlr activity modulators
IN2012DN02736A (en)
MX2009006760A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
BR112014018815A8 (en) IMMUNOGENIC COMPOSITION COMPRISING PROTEIN-X POLYSACCHARIDE CONJUGATE FROM N. MENINGITIDIS
UA99659C2 (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
CO6160335A2 (en) VACCINE
CL2007001698A1 (en) Immunogenic composition comprising the meningococcal lipooligosaccharides (los) of immunotypes l2 and l3 of neisseric strains; vaccine composition that comprises it; preparation procedure; and its use for the prevention or treatment of diseases caused by one or more serogroups of n. meningitidis
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
BR112012007876A2 (en) "ion exchange membranes"
MX2009008928A (en) Compositions comprising polysaccharide conjugates and their use as vaccines.
IN2014DN09791A (en)
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
BR112015024014A2 (en) conjugate vaccine
BR112013023354A2 (en) equine rhinitis vaccine
BRPI0713274A2 (en) combination of vaccines for the protection of fish against streptococcal infection, and method for preparing a combination of vaccines
WO2007073706A3 (en) Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations
TN2010000338A1 (en) Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF